Tag: Cellestial
-
Strategic Win: Preclinical Development Consultation with L2D
Cellestial Health is one of the preclinical-stage companies that was recently selected for a free consultation with the top experts at Leads to Development (L2D) regulatory consultancy, Jonathan Kearsey and Vincent Dubois. This will provide confidential guidance and advice on the path to the regulatory approval of the first Cellestial drug asset. As Nat Hastings,…
-
Finalists: JP Morgan Life Sciences Innovation Summit
Cellestial Health has been named as one of the 10 global finalists in the Second Annual Life Sciences Innovation Summit organised by J.P. Morgan Asset Management’s Life Sciences Private Capital and King Abdullah International Medical Research Center (كيمارك KAIMRC), alongside EpiBone, Inc., FimmCyte Therapeutics, Genethon NewCo, NanoPalm | نانو بالم, Neurenati Therapeutics, Rinri Therapeutics, Script Biosciences,…
-
OBN BioSeed: Raising Awareness
On Monday 9th of June, Dr Nat Hastings presented the developments and plans of Cellestial Health at the annual #BioSeed event, where pitches are delivered by companies looking for Seed funding. At the moment, Cellestial is only preparing for its Seed funding round. What are the benefits of our early discussion with the investor community?…
-
Academic Collaboration: Opportunities and Challenges
Last week Dr Nat Hastings, CEO of Cellestial Health, had a pleasure of contributing to a panel discussion on early-stage biopharmaceutical company funding at #BioIntegrates. This conference was organised by Life Science Integrates, hosted at the Anglia Ruskin University in Cambridge. Cellestial had a unique perspective to bring to this discussion – that of an…
-
Cellestial Health Closes Pre-Seed Equity Round
Cellestial Health, a pioneering pharmaceutical development spin-out from the University of Cambridge, has closed a £515,000 pre-seed equity funding round to accelerate the development of novel therapeutics targeting astrocytes, an often-overlooked cell type in the brain, with the first indication of Parkinson’s disease. The equity round was led by Zinc VC, with the latest investment…
-
New Collaboration Alert: o2h Discovery and Cellestial
Cellestial Health joins forces with o2h in drug discovery as an awardee of the latest Kickstrater Award. o2h discovery is a collaborative Contract Research Organisation which has an integrated drug discovery platform in Ahmedabad (India) and Cambridge (UK). o2h offer a multi-modality integrated drug discovery platform to support their collaborators developing the next generation of…
-
One Nucleus #BioWednesday: Ones to Watch
Cellestial Health team gather in person at the #BioWednesday event by One Nucleus after an evening of pitches and networking at Queen Mary Bioenterprises – as a largely virtual company, we are more used to seeing each other in 2D! Thank you to Tony Jones, Alicia Gailliez, and the whole team at One Nucleus for…
-
Winning Pitch at Founders Live Cambridge
Friends, There are around 3 billion people affected by neurological conditions in the world, of which approximately 10 million have Parkinson’s. There is no cure, and most new treatments for Parkinson’s aim to protect brain cells called neurones. However, did you know that neurones only represent around half of our brains?So, can we hope to…
-
#21toWatch 2025: Winners!
What an incredible honour to be acknowledged as one of the most innovative companies in the East of England this year at #21toWatch campaign ✨ Supported by the cofinitive team including Faye Holland, Gemma Dorling, and Carole Aye Maung, and meticulously judged by Christine Martin, Chris Ellis, Thomas Hughes, and Jo Słota-Newson, the event on…
-
#21toWatch 2025: Proud to be Short-Listed!
Friends, Cellestial Health is honoured to be shortlisted in the prestigious #21toWatch Companies list – among other impressive contestants such as Lucy Jung, co-founder of Charco Neurotech, and Jonathan Fisher. Both of these inventors are working on wearable devices to reduce motor symptoms of Parkinson’s. At the same time, Arko Paul at Oltera is designing…